The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

Exact Sciences Stock: Beats Its Own Guide Total second-quarter revenue climbed 12% to $699.3 million, above expectations for $690 million and Exact's own guidance for $677 million to $697 million ...

Key Points Exact Sciences has the potential to be a big name in cancer testing and screening in the future. It already has multiple tests, and is working on one that can screen for multiple cancers.

Exact Sciences Corporation lost $1.13 a share on $2.5 billion in sales in FY2023. The current analyst firm consensus sees similar per share losses in FY2024, even as sales rise to $2.83 billion.

Exact Sciences’ proprietary technology platform, Exact Nexus, enabled electronic connections with nearly 0.25 million providers who ordered Cologuard this year, along with 24 million patients ...

A n updated version of Exact Sciences’ stool-based colorectal cancer screening test detected cancer accurately in a massive study, triggering fewer false alarms than its current product, the ...

Exact Sciences said first-quarter revenue increased 6% year-over-year to $638 million, which beat the consensus estimate of $627.355 million, according to Benzinga Pro. The company reported a ...

Summary According to ARK’s research, Exact Sciences has been a pioneering force in the growing field of oncology testing and will likely remain so during the next five years. Exact’s ...

Last year, Exact Sciences burned through $223.6 million in cash just from its day-to-day operations. And that was a significant increase from the $102.2 million it used up in the previous year.